Form 8-K Centessa Pharmaceuticals For: Nov 05
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/26/2026
- Equities end higher as Anthropic's IPO filing buoys AI stocks
- Anthropic files for Nasdaq IPO as revenue jumps to $16.3 billion
- Meta reverses losses to rise as investors weigh $35 billion AI funding plan
- Post-election relief ahead for markets, says Morgan Stanley
- Musk says SpaceX raised $40 billion in debt, warns of neocloud collapse
- Brazil’s Lula wins historic fourth term, Flavio Bolsonaro refuses to concede
- Microsoft to offer buyouts to 60,000 workers in cost-cutting move - Bloomberg
- Borr Drilling rig sinks off Gabon, one person dead and four missing
- Oil settles lower on peace hopes, Saudi attacks limit losses
- JetBlue shares drop on creditor restructuring news amid bankruptcy filing fears
Truist Securities Comments on Centessa Pharmaceuticals (CNTA) Amid 18pct Drop
November 5, 2025 8:03 AM ESTTruist Securities analyst Danielle Brill reiterated a Buy rating and $30.00 price target on Centessa Pharmaceuticals (NASDAQ: CNTA).
The analyst comments "CNTA shared the highly anticipated preliminary Ph 2a data with ORX750 in narcolepsy type 1 & 2 (NT1/NT2) and idiopathic hypersomnia (IH) this morning.... More



